Search Within

Lee M Krug

  1. "Department of Pathology and Laboratory Medicine"
Formats
  1. Meeting Abstract (22)
  2. Journal Article (20)
  3. Book Section (3)
Groups
  1. Department of Pathology and Laboratory Medicine (45)
  2. Department of Medicine (37)
  3. Solid Tumor Oncology Division (36)
  4. Thoracic Oncology (35)
  5. GSK Faculty (26)
  6. Surgery (17)

More Groups

People
  1. Mark Kris (25)
  2. William Travis (25)
  3. Maria Pietanza (20)
  4. Marc Ladanyi (14)
  5. Valerie Rusch (14)
  6. Camelia Sima (12)

More People

Years
  1. 2016 (4)
  2. 2015 (7)
  3. 2014 (6)
  4. 2013 (6)
  5. 2012 (6)
  6. 2011 (4)

More Years

Publications
  1. Journal of Clinical Oncology (13)
  2. Journal of Thoracic Oncology (13)
  3. Clinical Cancer Research (4)
  4. Lung Cancer (3)
  5. Cancer Chemotherapy and Pharmacology (2)
  6. Annals of Oncology (1)

More Publications

Publishers
  1. Elsevier Inc. (14)
  2. American Society of Clinical Oncology (13)
  3. American Association for Cancer Research (4)
  4. Elsevier Ireland Ltd. (3)
  5. Springer (3)
  6. Wolters Kluwer Health | Lippincott Williams & Wilkins (3)

More Publishers

Results (45)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The International Association for the Study of Lung Cancer Lung Cancer staging project: Proposals for the revision of the clinical and pathologic staging of small cell lung cancer in the forthcoming eighth edition of the TNM classification for lung cancer
    Journal Article

    Nicholson, A. G.; Chansky, K.; Crowley, J.; Beyruti, R.; Kubota, K.; Turrisi, A.; Eberhardt, W. E. E.; Van Meerbeeck, J.; Rami-Porta, R.; on behalf of the Staging and Prognostic Factors Committee, Advisory Boards, and Participating Institutions
    Journal of Thoracic Oncology (2016)

    Fulltext@MSK | Save
  • A multi-center, randomized, double-blind phase II study comparing temozolomide (TMZ) plus either veliparib (ABT-888), a PARP inhibitor, or placebo as 2nd or 3rd-line therapy for patients (Pts) with relapsed small cell lung cancers (SCLCs)
    Meeting Abstract

    Pietanza, M. C.; Krug, L. M.; Waqar, S. N.; Dowlati, A.; Hann, C. L.; Chiappori, A.; Owonikoko, T. K.; Woo, K.; Bensman, Y.; Hurtado, B.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • A phase I trial of the Hedgehog inhibitor, sonidegib (LDE225), in combination with etoposide and cisplatin for the initial treatment of extensive stage small cell lung cancer
    Journal Article

    Pietanza, M. C.; Litvak, A. M.; Varghese, A. M.; Krug, L. M.; Fleisher, M.; Teitcher, J. B.; Holodny, A. I.; Sima, C. S.; Woo, K. M.; Ng, K. K.; more...
    Lung Cancer (2016)

    Fulltext@MSK | Save
  • Small cell lung cancer: Can recent advances in biology and molecular biology be translated into improved outcomes?
    Journal Article

    Bunn, P. A. Jr; Minna, J. D.; Augustyn, A.; Gazdar, A. F.; Ouadah, Y.; Krasnow, M. A.; Berns, A.; Brambilla, E.; Rekhtman, N.; Massion, P. P.; more...
    Journal of Thoracic Oncology (2016)

    Fulltext@MSK | Save
  • Small cell and other neuroendocrine tumors of the lung
    Book Section

    Pietanza, M. C.; Krug, L. M.; Wu, A. J.; Kris, M. G.; Rudin, C. M.; Travis, W. D.
    In DeVita, V. T. Jr; Lawrence, T. S.; Rosenberg, S. A. (Eds.) DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology. 10th ed (2015)

    Fulltext@MSK | Save
  • BAP1 inactivation in mesothelioma is highly prevalent
    Meeting Abstract

    Zauderer, M.; Cercek, A.; Rimner, A.; Rusch, V.; Adusumilli, P. S.; Nash, G. M.; Moreira, A.; Hmeljak, J.; Ladanyi, M.; Krug, L. M.
    Journal of Thoracic Oncology (2015)

    Fulltext@MSK | Save
  • Comprehensive mutation analysis of never-smokers with small cell lung cancer (SCLC)
    Meeting Abstract

    Pietanza, M. C.; Won, H.; Krug, L. M.; Varghese, A. M.; Riely, G. J.; Rekhtman, N.; Wang, L.; Travis, W. D.; Zakowski, M.; Ladanyi, M.; more...
    Journal of Thoracic Oncology (2015)

    Fulltext@MSK | Save
  • The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers
    Journal Article

    Ujiie, H.; Kadota, K.; Nitadori, J. I.; Aerts, J. G.; Woo, K. M.; Sima, C. S.; Travis, W. D.; Jones, D. R.; Krug, L. M.; Adusumilli, P. S.
    OncoImmunology (2015)

    Fulltext@MSK | Save
  • Prospective molecular analysis of small cell lung cancer (SCLC) using next generation sequencing (NGS)
    Meeting Abstract

    Pietanza, M. C.; Won, H. H.; Rekhtman, N.; Wang, L.; Travis, W. D.; Krug, L. M.; Varghese, A. M.; Paik, P. K.; Riely, G. J.; Zakowski, M. F.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Response to crizotinib and cabozantinib in stage IV lung adenocarcinoma patients with mutations that cause MET exon 14 skipping
    Meeting Abstract

    Paik, P. K.; Drilon, A. E.; Yu, H. A.; Krug, L. M.; Rekhtman, N.; Borsu, L.; Ginsberg, M. S.; Berger, M. F.; Ladanyi, M.; Rudin, C. M.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save